Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.
|
| Abstract |
We retrospectively reviewed for 72 relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem-cell transplantation (ASCT) treated between 2004 and 2017, efficacy and safety profile of rituximab (375 mg/m2) in combination with etoposide (300 mg/m2) and ifosfamide (1500 mg/m2) at 2, 3, or 4-week intervals. Median age was 79 years (range, 64-92). The median number of previous line was 1 (range 1-8). Patients received a median of six cycles (1-12). Fourteen patients (19%) presented partial and 14 complete responses (19%). Among the 369 cycles, nine patients developed febrile neutropenia (13%), 14 a grade 3-4 neutropenia (19%), 7 a grade 3-4 thrombocytopenia (10%) without grade 3-4 non-hematological toxicity. With a median follow up of 7.8 months, the median progression-free survival, overall survival, and duration of response were 4.4 months, 9.4 months, and 12 months, respectively. This regimen represents a therapeutic option in R/R DLBCL patients ineligible to ASCT.
|
|---|---|
| Authors | Guillaume Aussedat, Delphine Maucort-Boulch, Philippe Rey, Violaine Safar, Lionel Karlin, Mad Helenie Elsensohn, Emmanuel Bachy, Laure Lebras, Bertrand Favier, Nicolas Vantard, Dana Ghergus, Camille Golfier, Pierre Sesques, Anne Lazareth, Hélène Lequeu, Emmanuelle Ferrant, Gilles Salles, Emmanuelle Nicolas-Virelizier, Hervé Ghesquieres |
| Journal | Leukemia & lymphoma (Leuk Lymphoma) Vol. 63 Issue 3 Pg. 599-607 (03 2022) ISSN: 1029-2403 [Electronic] United States |
| PMID | 34720034 (Publication Type: Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!